QCS（QUALITY CONTROL SOLUTIONS LTD.）

What QCS（QUALITY CONTROL SOLUTIONS LTD.） does

QCS (Quality Control Solutions Ltd.) is a Shenzhen, China-based pharmaceutical reference material producer founded in 2013 (re-incorporated 2021) that supplies impurity reference standards, API reference standards, metabolites, drug analogues, and isotope-labeled standards to pharmaceutical companies, testing laboratories, and research institutions worldwide. The company operates ISO 17034:2016-accredited manufacturing with a 400 MHz NMR, LC-MS, HPLC, GC, IR, and UV instrument base of 100+ analytical instruments, and offers a catalog of 81,344+ compounds with 23,563+ in stock — the largest such catalog in China according to company claims.

QCS's technology stack centers on classical analytical chemistry plus preparative chromatography (prep HPLC, SFC) and a 2023-vintage joint Chiral Standard Impurity Joint Laboratory with Guangzhou R&Chiral that adds chiral separation capability (chiral HPLC, chiral columns). Service offerings include impurity isolation and identification, custom synthesis, and preparative-scale separation, all delivered with comprehensive analytical data packages (COA, MS, NMR, HPLC spectra). The company has demonstrated regulatory depth by successfully identifying and correcting a structural error in the European Pharmacopoeia's Flucloxacillin Impurity J monograph, an outcome EDQM subsequently acknowledged.

The business model is direct B2B catalog sales through qcsrm.com with mg-quantity pack sizes (10/25/50/100mg), quote-based custom synthesis pricing, and worldwide shipping. Go-to-market combines a multilingual e-commerce storefront (English, Chinese, Spanish, Portuguese) with content marketing via 94+ technical articles on impurity research, stability studies, and chiral separation. QCS holds National High-tech Enterprise certification in China and reports 5,800+ cumulative global customers since founding, with management led by Chairman Juncai Lai and General Manager Fuqiang Qiu. No revenue, funding, or ownership data is publicly disclosed.

Name

QCS（QUALITY CONTROL SOLUTIONS LTD.）

Legal name

QUALITY CONTROL SOLUTIONS LTD.

Website

https://qcsrm.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

QCS (Quality Control Solutions Ltd.) is a Shenzhen-based, ISO 17034-accredited pharmaceutical impurity reference standard producer serving pharmaceutical companies, testing laboratories, and research institutions globally with a catalog of 81,344+ compounds and custom synthesis services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Reference Materials

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833), Wholesale-Chemicals & Allied Products (5160)

akta.pro primary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

akta.pro secondary industries

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Analytical Testing & QC Release Services (potency, purity, sterility) (HLAAAKAG)

Keywords

• Pharmaceutical reference materials
• Impurity reference standards
• API reference standards
• Custom synthesis services
• Chiral separation services

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Impurity Reference Standards Sales: QCS generates revenue primarily through the sale of pharmaceutical impurity reference standards, metabolites, drug analogues, API reference standards, isotope-labeled reference standards, and related chemical reference materials. Products are sold in catalog quantities (e.g., 10mg, 25mg, 50mg, 100mg pack sizes) via a direct B2B sales model to pharmaceutical companies, testing labs, and research institutions. The company also provides custom synthesis services and impurity preparation/isolation technical services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

QCS produces and sells pharmaceutical impurity reference standards, API reference standards, metabolites, drug analogues, and isotope-labeled reference materials (81,344+ catalog compounds, 23,563+ in stock). The company also provides one-stop services including impurity isolation, identification, custom synthesis, and preparative chromatography separation for pharmaceutical companies, testing laboratories, and research institutions. Each compound is fully characterized by NMR, LC-MS, HPLC, GC, IR, and UV, with COA, MS, NMR, and HPLC spectra supplied.

Product overview

QCS (Quality Control Solutions Ltd.) is a pharmaceutical reference material supplier offering a comprehensive portfolio of impurity reference standards and API calibration standards. The core product lines include pharmaceutical impurity reference standards characterized by NMR, LCMS, HPLC, GC, IR and UV techniques, API reference standards, metabolites, and drug analogues. The company provides related services including impurity isolation, identification, custom synthesis, and preparative chromatography separation. With over 81,344 compounds available and 23,563 in stock, QCS serves pharmaceutical companies, testing laboratories, and research institutions globally through ISO 17034 accredited manufacturing processes.

Differentiator

Problem solved

Functional benefit

Brands

• Chiral Standard Impurity Joint Laboratory (with Guangzhou R&Chiral): A joint laboratory co-founded by QCS R&D Center and Guangzhou R&Chiral for chiral separation research and development, inaugurated on July 26, 2023.

Products and services

• Pharmaceutical Impurity Reference Standards Certified reference materials for pharmaceutical impurities, providing precise identification and quantification of impurity compounds in drug quality control. Each compound is characterized by NMR, LCMS, HPLC, GC, IR, and UV, with COA, MS, NMR, and HPLC spectra provided. For pharmaceutical companies, testing laboratories, and research institutions.
• API Reference Standards Active Pharmaceutical Ingredient reference standards for calibration and verification of analytical methods in pharmaceutical manufacturing and testing. For pharmaceutical companies and testing laboratories.
• Metabolites Drug metabolite reference standards for pharmaceutical research and development, supporting metabolic pathway studies and drug metabolism analysis. For pharmaceutical research institutions and drug developers.
• Drug Analogues Structural analogues of pharmaceutical compounds used as reference materials in drug development and impurity profiling studies. For pharmaceutical research and development teams.
• Impurity Isolation & Identification Services One-stop services for impurity isolation, identification, synthesis, and analytic release, providing comprehensive drug quality research support. For pharmaceutical companies requiring specialized analytical work.
• Custom Synthesis Services Custom synthesis of pharmaceutical impurities and reference standards, including high-purity impurity reference standards (purity ≥ 95%) with COA, MS, NMR, and HPLC spectra. For pharmaceutical companies and research institutions with specialized impurity needs.
• Impurity Preparation & Separation Services Preparation and separation services for pharmaceutical impurities using advanced chromatography techniques including preparative HPLC and SFC. For pharmaceutical companies and research institutions requiring impurity isolation.
• Preparative Chromatography Services Semi-preparative and preparative chromatography services using advanced column technology for impurity separation and purification, featuring C18, C8, amino, phenyl, and hydrophilic stationary phases. For pharmaceutical companies requiring preparative-scale separations.
• Chiral Separation Services Chiral separation methods (SFC and chiral HPLC), chiral reference standards, and chiral control strategies delivered through the Chiral Standard Impurity Joint Laboratory with Guangzhou R&Chiral. For pharmaceutical companies requiring chiral impurity standards and separation.

Quantifiable outcome

• ISO 17034 re-evaluation passed with zero non-conformances (2024)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Guangzhou Research& Creative Biotechnology Co., Ltd. (Guangzhou R&Chiral)strategicTechnology or Integration · 26 July 2023QCS and Guangzhou R&Chiral co-founded the 'Chiral Standard Impurity Joint Laboratory' at the QCS Standard Material R&D Center. The partnership combines QCS's pharmaceutical impurity research capabilities and analytical instrumentation with Guangzhou R&Chiral's chiral chromatography column technology. The joint laboratory aims to promote domestically produced chiral chromatography products, establish a chiral standard testing system tailored for Chinese requirements, enrich China's chiral standard separation database, and accelerate domestic substitution of imported chiral chromatography products. Chairman Juncai Lai and General Manager Fuqiang Qiu from QCS attended the inauguration alongside Chairman and CEO Zhiping Mao from Guangzhou R&Chiral.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• United States Pharmacopeia (USP): USP is the official pharmacopeia of the United States and a primary source of pharmacopoeial reference standards for drug quality control. While not a commercial competitor in the same sense, USP's standards are the benchmark against which QCS's pharmacopoeial and non-pharmacopoeial reference materials are qualified.
• Pharmaron: Pharmaron is a China-headquartered CRO/CDMO providing drug discovery, custom synthesis, and analytical chemistry services to global pharmaceutical clients. Its analytical chemistry and impurity characterization services overlap with QCS's impurity isolation, identification, and custom synthesis offerings.
• European Directorate for the Quality of Medicines (EDQM): EDQM manages the European Pharmacopoeia and supplies official reference standards used across EU regulatory submissions. EDQM directly competes with QCS in the European pharmacopoeial reference standards market and is the authority that recognized QCS's correction to the Flucloxacillin Impurity J structural formula.
• WuXi AppTec: WuXi AppTec is a leading global CRO/CDMO offering comprehensive pharmaceutical R&D services including custom synthesis, analytical services, and reference material support. While broader in scope, WuXi's analytical and reference-related offerings overlap with QCS's higher-margin custom synthesis and analytical release services in the Chinese market.
• Sigma-Aldrich (MilliporeSigma): MilliporeSigma, the life science business of Merck KGaA, is the world's largest supplier of analytical reference standards, certified reference materials, and impurity standards with a global catalog spanning pharma, food, and environmental markets. It is the dominant commercial benchmark against which QCS competes on catalog depth and global logistics.

Direct peers

• Tokyo Chemical Industry (TCI): TCI is a Japanese specialty chemicals manufacturer offering an extensive catalog of organic chemicals, reference standards, and pharmaceutical intermediates with strong positioning in Asia. Like QCS, TCI sells catalog reference materials with characterization data to pharmaceutical and research customers.
• Toronto Research Chemicals (TRC): TRC is a Canadian specialty supplier of impurity reference standards, metabolites, and stable isotope-labeled compounds serving pharmaceutical R&D. Acquired by LGC Group, TRC competes head-to-head with QCS in the pharmaceutical impurity catalog space and serves a similar customer base of pharma QA/QC and drug development scientists.
• Clearsynth: Clearsynth is an India-based specialty manufacturer of pharmaceutical impurity reference standards, API standards, and isotope-labeled compounds with ISO/IEC 17025 accreditation. It competes with QCS directly in the global pharmaceutical impurity catalog market, particularly for generic drug impurities and custom synthesis work.
• LGC Standards: LGC Standards is a major ISO 17034-accredited reference material producer offering pharmaceutical impurities, API standards, and certified reference materials globally. Following LGC's acquisition of Toronto Research Chemicals, it has emerged as one of the leading specialty impurity reference standard suppliers and a direct competitor to QCS in pharmaceutical impurity catalogs.

Emerging players

• CATO Research Chemicals: CATO is a Chinese specialty chemical manufacturer offering pharmaceutical intermediates, impurities, and reference standards with a focus on custom synthesis. As a fellow China-based specialty supplier, CATO competes with QCS for both domestic and international pharmaceutical impurity customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/qcsrm

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QCS（QUALITY CONTROL SOLUTIONS LTD.）